CD4 and neoplasm: The CD40 and CD40 ligand (CD40LG) interaction mediates anti-tumoral immune responses by increasing immunogenic cell death (ICD) of tumor cells, APC activation, tumor immunogenicity by up-regulating major histocompatibility complex (MHC) molecules, production of proinflammatory factors, costimulation of CD4+ and CD8+ T cells, and tumor cell susceptibility to T-cell lysis [2–4].